Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234572 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
A Phase 2 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT00234572: Completed Phase 2 study, sponsored by Ipsen.
NCT00234572 is a Phase 2 study that has completed, run by Ipsen. The registered enrollment target is 108 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00234572, a Phase 2 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness of lanreotide autogel to placebo after a single injection. Effectiveness and safety were then also assessed following four fixed-dose injections and after one year of treatment given at titrated doses.
Interventions
- DRUG Lanreotide (Autogel formulation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2000-05 |
| Est. Completion | 2003-01-03 |
| Phase | Phase 2 |
What the finished NCT00234572 record still lists
NCT00234572 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 1 intervention - of which Lanreotide (Autogel formulation) is the first listed.
NCT00234572 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00234572 about?
NCT00234572 is a clinical study titled "Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly". The purpose of this study is to compare the effectiveness of lanreotide autogel to placebo after a single injection. Effectiveness and safety were then also assessed following four fixed-dose injections and after one year of treatment given at titrated doses.
What is the current status of trial NCT00234572?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2000-05. Estimated completion is 2003-01-03.
What interventions are being tested in trial NCT00234572?
The interventions under investigation include: Lanreotide (Autogel formulation) (DRUG).
Who is sponsoring clinical trial NCT00234572?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00234572's enrollment target sits among peer trials
108 640th of 2000 higher than 1,355 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia